Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Repare Therapeutics's share price is $2.65.
Repare Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $0.28. Hence, Repare Therapeutics's PS Ratio for today is 9.60.
The historical rank and industry rank for Repare Therapeutics's PS Ratio or its related term are showing as below:
RPTX'
s PS Ratio Range Over the Past 10 Years
Min: 0.85 Med: 6.52 Max: 10650
Current: 9.6
During the past 8 years, Repare Therapeutics's highest PS Ratio was 10650.00. The lowest was 0.85. And the median was 6.52.
RPTX's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.35
vs RPTX: 9.60
During the past 8 years, Repare Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 457.80% per year. The lowest was 84.40% per year. And the median was 271.10% per year.
Back to Basics: PS Ratio
Repare Therapeutics (NAS:RPTX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Repare Therapeutics PS Ratio Related Terms
Repare Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Repare Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Repare Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repare Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Repare Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Repare Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Repare Therapeutics's Share Price of today is $2.65. Repare Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Repare Therapeutics (RPTX) has a PS Ratio of 9.60 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Repare Therapeutics and its competitors. This is 47% above median its historical median of 6.52. Over the past decade, Repare Therapeutics' PS Ratio has ranged from 0.85 to 10,650.00.
Is Repare Therapeutics' PS Ratio too high?
Repare Therapeutics' current PS Ratio of 9.60 is 47% above median its 10-year median of 6.52. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 10,650.00. The Biotechnology industry median PS Ratio is 9.35. Repare Therapeutics' value of 9.60 is 2.7% above this industry median. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' PS Ratio compare to MGNX and THAR?
Repare Therapeutics' PS Ratio of 9.60 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.35. Repare Therapeutics' value of 9.60 is 2.7% above this benchmark. Historically, Repare Therapeutics' own PS Ratio has ranged from 0.85 to 10,650.00 over the past decade. While the company's 10-year median is 6.52 vs. the industry median of 9.35, Repare Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.35, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repare Therapeutics's current PS Ratio of 9.60 is 2.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Repare Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repare Therapeutics's current PS Ratio is 9.60, which is 47% above median its own 10-year median of 6.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current PS Ratio of 9.60. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current PS Ratio is 9.60, which is 47% above median its 10-year median of 6.52 and 2.7% above the Biotechnology industry median of 9.35. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current PS Ratio is 9.60 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repare Therapeutics (RPTX) Overvalued in 2026?
Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued.
The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.
Key valuation signals for RPTX:
PS Ratio: 9.60 (47% above median its 10-year median of 6.52)
GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
Industry Position: 2.7% above the Biotechnology median
No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score
Get the complete analysis for RPTX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPTX has been successfully added to your 
